All News

Found 387 articles

• Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients

  2/21/2023

  Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive data from three retrospective real-world studies which demonstrated that initiation of Veklury® (remdesivir) within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity.

• IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial

  2/13/2023

  IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”) today announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S (“MVP-S”), in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma (“r/r DLBCL”).

• Hologic Announces Financial Results for First Quarter of Fiscal 2023

  2/1/2023

  Hologic, Inc. announced the Company’s financial results for the fiscal first quarter ended December 31, 2022.

• Accuray Reports Fiscal 2023 Second Quarter Financial Results

  2/1/2023

  Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter of fiscal 2023 ended December 31, 2022.

• IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S

  1/8/2023

  IMV Inc., a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, outlined its planned 2023 milestones to advance the clinical development of its lead therapeutic, maveropepimut-S.

• 

  BioSpace Layoff Tracker 2022: Axcella Therapeutics, TherapeuticsMD, Instil Bio and More Cull Staff

  12/15/2022

  The layoffs trend in the life sciences industry is continuing into the final months of 2022. See inside for details on which companies are reducing staff to increase cash flow.

• IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL

  12/15/2022

  IMV Inc. today announced positive initial patient data from the VITALIZE Phase 2B trial evaluating its lead DPX product, MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma (“r/r DLBCL”) who received at least three previous lines of treatment.

• IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split

  12/13/2022

  IMV Inc. (the “Corporation” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced that its common shares commence trading post consolidation today.

• IMV Shareholders Approve Reverse Stock Split at 88%

  12/7/2022

  IMV Inc. announced that at the special meeting of shareholders held on December 7, 2022, the share consolidation as described in the management information circular filed on October 28, 2022 was approved by the shareholders at 87.87% of the shares voted and that its board of directors has approved a 1-for-10 reverse stock split of IMV’s common shares immediately thereafter.

• Hologic Ranked #1 for Mammography System Performance and Customer Satisfaction for 10th Consecutive Year

  12/1/2022

  Hologic Ranked #1 for Mammography System Performance and Customer Satisfaction for 10th Consecutive Year.

• Shimadzu Medical Systems USA receives an IMV ServiceTrak Award in the R/F Systems category

  11/28/2022

  Shimadzu Medical Systems USA , a subsidiary of Shimadzu Corporation, receives an IMV ServiceTrak Award in the R/F Systems category.

• IMV announces the first wave of the 2022 IMV ServiceTrak™ Imaging Awardees at RSNA

  11/28/2022

  Today IMV, part of Science and Medicine Group, the leading market research and business intelligence provider to the laboratory diagnostic industry, announced the category winners of the 2022 IMV ServiceTrak™ Imaging Awards.

• Accuray Receives IMV Award for Best In Service in Radiation Oncology for 2022

  11/28/2022

  Accuray Incorporated (NASDAQ: ARAY) announced today that its commitment to delivering better, faster cancer treatment technology and superior service is resulting in highly satisfied customers.

• Diagnostic Imaging Services Market Revenue to Surpass USD 545.7 BN by 2030

  11/21/2022

  According to Nova one advisor, the global Diagnostic Imaging Services market size is expected to hit around USD 545.7 billion by 2030 from valued at USD 364.2 billion in 2022 and growing at a CAGR of 5.10% from 2022 to 2030.

• Oncology Cancer Drugs Market Revenue to Surpass USD 289.2 BN by 2030

  11/16/2022

  According to Nova one advisor, the global Oncology Cancer Drugs market was valued at USD 147.2 billion in 2021 and it is expected to hit around USD 289.2 billion by 2030 with a CAGR of 8.4% during the forecast period 2022 to 2030.

• Regenerative Medicine Market Size to Hit USD 60.08 Billion by 2030

  11/14/2022

  According to Nova one advisor, the global Regenerative Medicine market size was estimated at USD 27.85 billion in 2021 and is expected to surpass around USD 60.08 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 14.27% during the forecast period 2022 to 2030.

• 

  Movers & Shakers: Odyssey, Daiichi Sankyo, Atsena and More

  11/11/2022

  While Biogen and Seagen made the biggest C-suite splashes this week, other companies across the biopharma industry also bolstered their leadership teams with new talent.  

• Cell Lysis and Disruption Market Size is Expanding USD 7.1 Billion by 2030

  11/11/2022

  As per Precedence Research, the global cell lysis and disruption market size is expanding around US$ 7.1 billion by 2030 and growing at a CAGR of 6.7% from 2021 to 2030.

• IMV Inc. Announces Third Quarter 2022 Financial and Operational Results

  11/10/2022

  IMV Inc., a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced its financial and operational results and provided an update for the third quarter ended September 30, 2022.

• IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022

  11/8/2022

  IMV Inc. today announced that it will hold a conference call and webcast on Friday, November 11, 2022, at 8:00 a.m. ET to discuss the company’s 2022 third quarter financial and operational results.